A Phase 3, Randomized, Active Comparator-Controlled Clinical Trial to Study the Safety and Efficacy of MK0826 and Meropenem in Patients With Complicated UTI.

Trial Profile

A Phase 3, Randomized, Active Comparator-Controlled Clinical Trial to Study the Safety and Efficacy of MK0826 and Meropenem in Patients With Complicated UTI.

Discontinued
Phase of Trial: Phase III

Latest Information Update: 24 Mar 2017

At a glance

  • Drugs Ertapenem (Primary) ; Meropenem
  • Indications Urinary tract infections
  • Focus Therapeutic Use
  • Sponsors Merck & Co
  • Most Recent Events

    • 28 Apr 2012 Additional locations added as reported by European Clinical Trials Database record.
    • 28 Apr 2012 Planned number of patients changed from 410 to 680 as reported by European Clinical Trials Database record.
    • 12 Feb 2010 Actual end date changed from May 2009 to Jun 2009 as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top